Therapeutic Area Director
+11 year(s) experience
He stays abreast of market developments, generating and curating data sources, and distilling these into reports that enable clients to gain a competitive edge.
Since joining Pharma Intelligence in 2010, Daniel has tracked and forecast all the leading neurology, psychiatry, and pain drug markets. He is particularly interested in the shifting landscape of the multiple sclerosis market well as the implications of trial failures – alongside the successes in Alzheimer's disease R&D.
He has helped expand research and insight on rare diseases , including established orphan drug markets as well as as emerging opportunities. He also attends international medical conferences and enjoys collaborating with colleagues at Scrip.
Daniel has a First Class degree in Natural Sciences from the University of Bath.